The Impetigo drugs in development market research report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Impetigo. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Impetigo and features dormant and discontinued products.

GlobalData tracks seven drugs in development for Impetigo by eight companies/universities/institutes. The top development phase for Impetigo is preclinical with three drugs in that stage. The Impetigo pipeline has five drugs in development by companies and two by universities/ institutes. Some of the companies in the Impetigo pipeline products market are: Grupo Ferrer Internacional, Maruho and Tokyo University of Agriculture and Technology.

The key targets in the Impetigo pipeline products market include DNA Gyrase (EC 5.99.1.3), DNA Topoisomerase IV (EC 5.99.1.3), and Isoleucine tRNA Ligase Cytoplasmic (Isoleucyl tRNA Synthetase or IARS or EC 6.1.1.5).

The key mechanisms of action in the Impetigo pipeline product include DNA Topoisomerase IV (EC 5.99.1.3) Inhibitor with one drug in Phase III. The Impetigo pipeline products include two routes of administration with the top ROA being Topical and four key molecule types in the Impetigo pipeline products market including Small Molecule, and Synthetic Peptide.

Impetigo overview

Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria, streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions, and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, diabetes, and a compromised immune system. Treatment includes antibiotics.

For a complete picture of Impetigo’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.